Stoke Therapeutics, Inc. (STOK) Tops Q3 EPS by 7c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q3 EPS of ($0.47), $0.07 better than the analyst estimate of ($0.54). Revenue for the quarter came in at $4.89 million versus the consensus estimate of $3.64 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Golden Spike Resources plans name change, share consolidation and C$500K raise
• Kaiser Aluminum names Fred Stephan as CEO, effective November 2026